Literature DB >> 15217925

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

Peter F Bross1, Robert Kane, Ann T Farrell, Sophia Abraham, Kimberly Benson, Margaret E Brower, Sean Bradley, Jogarao V Gobburu, Anwar Goheer, Shwu-Luan Lee, John Leighton, Cheng Yi Liang, Richard T Lostritto, William D McGuinn, David E Morse, Atiqur Rahman, Lilliam A Rosario, S Leigh Verbois, Grant Williams, Yong-Cheng Wang, Richard Pazdur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15217925     DOI： 10.1158/1078-0432.CCR-03-0781

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  109 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  A panel of subunit-selective activity-based proteasome probes.

Authors:  Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Boudewijn A Duivenvoorden; Gijsbert A van der Marel; Bogdan I Florea; Alexei F Kisselev; Herman S Overkleeft
Journal:  Org Biomol Chem       Date:  2010-05-06       Impact factor: 3.876

3.  Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format.

Authors:  Xufan Tian; Nigora S Isamiddinova; Raymond J Peroutka; Seth J Goldenberg; Michael R Mattern; Benjamin Nicholson; Craig Leach
Journal:  Assay Drug Dev Technol       Date:  2010-12-06       Impact factor: 1.738

4.  Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins.

Authors:  Jeffrey G Marblestone; James P Larocque; Michael R Mattern; Craig A Leach
Journal:  Biochim Biophys Acta       Date:  2012-06-18

5.  Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

Authors:  Bilal A Azakir; Sabrina Di Fulvio; Jochen Kinter; Michael Sinnreich
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

6.  A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.

Authors:  Shinji Iwasaki; Andy Zhu; Michael Hanley; Karthik Venkatakrishnan; Cindy Xia
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

Review 7.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

8.  Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Authors:  Changyou Li; Rongxiu Li; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

9.  A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Authors:  Owen A O'Connor; A Keith Stewart; Marcy Vallone; Christopher J Molineaux; Lori A Kunkel; John F Gerecitano; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

10.  Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.

Authors:  Changyou Li; Daniel E Johnson
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.